Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

1. Etanercept (Nepexto)

Etanercept (Nepexto) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/167604/2020 EMEA/H/C/004711 Nepexto (etanercept) An overview of Nepexto and why it is authorised in the EU (...) in children, see the package leaflet or contact your doctor or pharmacist. Nepexto is a ‘biosimilar medicine’. This means that Nepexto is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Nepexto is Enbrel. For more information on biosimilar medicines, see here. Nepexto contains the active substance etanercept. How is Nepexto used? Nepexto can only be obtained with a prescription and is available for injection under

2020 European Medicines Agency - EPARs

2. Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. (Full text)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. In 2016, SB4 (Benepali®) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and clinical comparisons, outstanding questions remain on SB4 use in routine practice.A systematic search for publications on real-world evidence of SB4 effectiveness, safety and drug survival was undertaken using search terms (SB4 OR Benepali (...) OR biosimilar etanercept OR innovator etanercept) in the BIOSIS® Toxicology, BIOSIS Previews®, Embase® and MEDLINE® databases up to 17 January 2019.Of 959 articles identified, eight journal articles, two journal letters and 23 congress abstracts were selected on criteria of original real-world evidence with a clinical focus. As expected with real-world evidence, quality scoring showed that the evidence had high external validity but lower internal validity. A total of 13,552 patients were described across

2020 Rheumatology and therapy PubMed abstract

3. Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review. (Full text)

Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review. Etanercept (ETN), a highly effective biological agent for the treatment of psoriasis (PSO) and psoriatic arthritis (PsA), is widely used in Spain. However, evidence of its economic impact is limited, indicating the need for a systematic review of the economic assessments conducted on the use of ETN in the treatment of both PSO and PsA in Spain.A systematic review was carried out

2020 Dermatology and therapy PubMed abstract

4. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial (Full text)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept for the treatment of patients with psoriatic arthritis (PsA).In this double-blind study, 851 patients with PsA were randomized to 1 of 3 treatment arms, as follows: oral methotrexate (20 mg) plus subcutaneous (...) placebo given weekly (n = 284), subcutaneous etanercept (50 mg) plus oral placebo given weekly (n = 284), or subcutaneous etanercept (50 mg) plus oral methotrexate (20 mg) given weekly (combination therapy; n = 283). The American College of Rheumatology 20% improvement (ACR20) response and Minimal Disease Activity (MDA) response at week 24 were the primary end point and key secondary end point, respectively. Other measures of inflammatory arthritis, radiographic progression, and nonarticular disease

2019 EvidenceUpdates PubMed abstract

5. Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial (Abstract)

Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial Patients with Kawasaki disease can develop life-altering coronary arterial abnormalities, particularly in those resistant to intravenous immunoglobulin (IVIg) therapy. We tested the tumor necrosis factor α receptor antagonist etanercept for reducing both IVIg resistance and coronary artery (CA) disease progression.In a double-blind multicenter trial, patients with Kawasaki disease received either etanercept (0.8 mg (...) ) and 13% (etanercept) of patients (P = .10). Etanercept reduced IVIg resistance in patients >1 year of age (P = .03). In the entire population, 46 (23%) had a coronary z score >2.5 at baseline. Etanercept reduced coronary z score change in those with and without baseline dilation (P = .04 and P = .001); no improvement occurred in the analogous placebo groups. Etanercept (n = 22) reduced dilation progression compared with placebo (n = 24) by algorithm in those with baseline dilation (P = .03

2019 EvidenceUpdates

6. Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial. (Full text)

Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial. Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of prescribed medications. To improve (...) the patient experience, a new phosphate-free formulation of etanercept was evaluated for reduced ISP associated with administration.This phase 3b, multicenter, randomized, double-blind, cross-over study compared the prior formulation of etanercept to a phosphate-free formulation. Etanercept-naïve adults with RA or PsA indicated for treatment with etanercept were eligible. Patients were randomized (1:1) to receive both etanercept formulations (50 mg) in one of two crossover sequences: prior formulation

2019 Rheumatology and therapy Controlled trial quality: predicted high PubMed abstract

7. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. (Full text)

Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. Research in rheumatoid arthritis (RA) is increasingly focused on the discovery of biomarkers that could enable personalized treatments. The genetic biomarkers associated with the response to TNF inhibitors (TNFi) are among the most studied. They include 12 SNPs exhibiting promising results in the three largest genome-wide association studies (...) (GWAS). However, they still require further validation. With this aim, we assessed their association with response to TNFi in a replication study, and a meta-analysis summarizing all non-redundant data. The replication involved 755 patients with RA that were treated for the first time with a biologic drug, which was either infliximab (n = 397), etanercept (n = 155) or adalimumab (n = 203). Their DNA samples were successfully genotyped with a single-base extension multiplex method. Lamentably, none

2019 PLoS ONE PubMed abstract

8. Etanercept

Etanercept Top results for etanercept - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for etanercept The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

9. Erelzi - Etanercept

Erelzi - Etanercept Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated to include post

2018 Health Canada - Drug and Health Product Register

10. Effects of Etanercept on the Patient-Perceived Results (PROs) in Patients with Moderate-To-Severe Plaque Psoriasis: Systematic Review of the Literature and Meta-Analysis. (Abstract)

Effects of Etanercept on the Patient-Perceived Results (PROs) in Patients with Moderate-To-Severe Plaque Psoriasis: Systematic Review of the Literature and Meta-Analysis. To evaluate the efficacy of etanercept (ETN) compared with placebo for moderate-to-severe psoriasis regarding patient-reported outcomes (PROs).Systematic review of studies retrieved by a sensitive search strategy in Medline, Embase, Cochrane Library.(population) studies had to include patients with for moderate-to-severe

2018 Journal of Dermatological Treatment

11. Brenzys, Etanercept

Brenzys, Etanercept Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated to include post

2018 Health Canada - Drug and Health Product Register

12. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Duarte A, Mebrahtu T, Goncalves P S, Harden M, Murphy R, Palmer S, Woolacott (...) N, Rodgers M & Rothery C. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Duarte A, Mebrahtu T, Goncalves P S, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M & Rothery C.. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology

2018 Health Technology Assessment (HTA) Database.

13. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. (Full text)

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. Matching-adjusted indirect comparison (MAIC) can be used to assess the comparative effectiveness of two treatments indirectly using data from randomized placebo-controlled trials. This MAIC assessed the comparative effectiveness of secukinumab (an anti-interleukin-17A) and etanercept (a tumor necrosis factor inhibitor) in a target (...) population of biologic-naïve patients with psoriatic arthritis (PsA).Individual patient data pooled from FUTURE 2 (NCT01752634), FUTURE 3 (NCT01989468), and FUTURE 5 (NCT02404350) (secukinumab: 150 mg, n=458 and 300 mg, n=461) were matched to data from the population in the NCT00317499 trial (etanercept 25 mg, n=101) using MAIC methodology, by adjusting for clinical and demographic baseline characteristics. Recalculated outcomes from FUTURE 2, 3, and 5 (150 mg, effective sample size (ESS) post-matching

2018 European journal of rheumatology Controlled trial quality: predicted high PubMed abstract

14. Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". (Full text)

Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". 29132866 2017 11 20 2018 12 02 1097-6787 77 6 2017 12 Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". e167-e168 S0190-9622(17)32062-5 10.1016/j.jaad.2017.05.063 Asahina Akihiko A Department of Dermatology, The Jikei (...) University School of Medicine, Tokyo, Japan. Electronic address: asahina-tky@umin.ac.jp. Nakagawa Hidemi H Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan. eng Letter Comment United States J Am Acad Dermatol 7907132 0190-9622 0 Antibodies, Monoclonal 0 Antibodies, Monoclonal, Humanized 0 Immunoglobulin G 0 Receptors, Tumor Necrosis Factor B72HH48FLU Infliximab FYS6T7F842 Adalimumab OP401G7OJC Etanercept IM J Am Acad Dermatol. 2015 Aug;73(2):329-31 26183982 J Am Acad

2017 Journal of the American Academy of Dermatology PubMed abstract

15. Reply to: Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". (Full text)

Reply to: Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". 29132867 2017 11 20 2018 12 02 1097-6787 77 6 2017 12 Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. Reply to: Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". e169-e170 S0190-9622(17)32058-3 10.1016/j.jaad.2017.06.155 No Daniel J DJ School of Medicine (...) FYS6T7F842 Adalimumab OP401G7OJC Etanercept IM J Am Acad Dermatol. 2017 Dec;77(6):e167-e168 29132866 Adalimumab Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Etanercept Humans Immunoglobulin G Infliximab Psoriasis Receptors, Tumor Necrosis Factor 2017 06 20 2017 06 24 2017 11 15 6 0 2017 11 15 6 0 2017 11 29 6 0 ppublish 29132867 S0190-9622(17)32058-3 10.1016/j.jaad.2017.06.155

2017 Journal of the American Academy of Dermatology PubMed abstract

16. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. (Full text)

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments currently licensed for psoriasis in children.To determine the clinical (...) effectiveness and cost-effectiveness of adalimumab, etanercept and ustekinumab within their respective licensed indications for the treatment of plaque psoriasis in children and young people.Searches of the literature and regulatory sources, contact with European psoriasis registries, company submissions and clinical study reports from manufacturers, and previous National Institute for Health and Care Excellence (NICE) technology appraisal documentation.Included studies were summarised and subjected

2017 Health technology assessment (Winchester, England) PubMed abstract

17. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment (Full text)

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA) who failed to respond (primary failure) or lost a satisfactory response (secondary failure) to adalimumab.All patients discontinued prior adalimumab treatment and continued methotrexate with etanercept 50 mg once weekly for 24 weeks. The primary (...) . In planned subgroup analyses, patients with anti-adalimumab antibodies and secondary adalimumab failure had the highest ACR20 response to etanercept at week 12 (11/17 patients; 64.7%). Among the patients with secondary adalimumab failure, those with anti-adalimumab antibodies were fivefold more likely to have an ACR20 response to etanercept than those without anti-adalimumab antibodies (odds ratio 5.2; 95% CI 2.0, 13.5; P < 0.001). Adverse events were reported for 62 (72.9%) patients and were consistent

2017 Rheumatology and therapy PubMed abstract

18. Efficacy and safety of etanercept in the treatment of sciatica: A systematic review and meta-analysis. (Abstract)

Efficacy and safety of etanercept in the treatment of sciatica: A systematic review and meta-analysis. Etanercept might be promising to alleviate sciatica caused by lumbar disc herniation and spinal stenosis. However, the results remained controversial. We conducted a systematic review and meta-analysis to evaluate the efficacy of etanercept in patients with sciatica. PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (...) (RCTs) and Controlled clinical trials (CCT) assessing the efficacy of etanercept on sciatica caused by lumbar disc herniation and spinal stenosis were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcome was leg pain scores. Meta-analysis was performed using random-effect model. Four RCTs and one CCT involving 184 patients were included in the meta-analysis. Overall, compared with placebo, etanercept could

2017 Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

19. Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials. (Abstract)

Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials. Patient-reported outcomes in psoriasis studies are assessed at specific study time points. If a treatment has not become effective by a certain time point, it may increase the likelihood of patients being dissatisfied and leaving a clinical study.To generate evidence concerning the number of patients dropping out of etanercept trials (...) over time including Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) data.Data from patients with psoriasis in 10 trials with etanercept were pooled. Analyses were performed for (i) patients who dropped out because of 'lack of efficacy' and (ii) patients who continued the trial. The PASI and DLQI data were summarized for different time points. The distribution of dropout over time, PASI, DLQI and the proportion of patients dropping out with given treatment

2017 British Journal of Dermatology

20. Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis

Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 21 April 2017 EMA (...) /CHMP/302222/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Erelzi International non-proprietary name: etanercept Procedure No. EMEA/H/C/004192/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/302222/2017 Page 2/81 Table of contents 1. Background information on the procedure 6 1.1. Submission of the dossier 6 1.2. Steps taken for the assessment of the product 8 2. Scientific

2017 European Medicines Agency - EPARs